Peptide lexicon
Semaglutid
Lipidated GLP-1 analogue with a half-life of about one week; approved as a medicinal substance in several products.
| Substance class | Peptide |
|---|---|
| CAS number | 910463-68-2 |
| Molecular formula | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molar mass | 4,114 g/mol |
| Synonyms | NN9535, GLP-1-Rezeptor-Agonist |
| PubChem | CID 56843331 |
Structure
Semaglutide is a 31-amino-acid peptide with 94 % homology to human GLP-1. An Aib residue at position 2 protects against DPP-4 degradation, and a C18 fatty-acid side chain on Lys26 mediates albumin binding.
State of research
Research covers GLP-1 receptor activation, glucose-dependent insulin secretion, gastric emptying and central appetite signalling. Large clinical trial programmes have been published.
Status
Semaglutide is an approved medicinal substance. The material offered here is a research reagent, not a medicinal product.
Literature
- Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-AnalysisJ ASEAN Fed Endocr Soc, 2022 · PMID 36578889 · DOI 10.15605/jafes.037.02.14
- Semaglutide for the treatment of overweight and obesity: A reviewDiabetes Obes Metab, 2023 · PMID 36254579 · DOI 10.1111/dom.14863
- Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trialsDiabetologia, 2024 · PMID 38613667 · DOI 10.1007/s00125-024-06144-1
- Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsAm J Cardiol, 2024 · PMID 38679221 · DOI 10.1016/j.amjcard.2024.04.041
- Semaglutide for the treatment of obesityTrends Cardiovasc Med, 2023 · PMID 34942372 · DOI 10.1016/j.tcm.2021.12.008
